Insmed price target raised to $95 from $70 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Insmed to $95 from $70 and keeps a Buy rating on the shares following the release of full data from the Phase 3 ASPEN trial for brensocatib at last week’s World Bronchiectasis Conference. The firm, which notes it has received “encouraging feedback” from bronchiectasis experts on the strength of the data and how broadly they expect to use brenso in their patients, continues to identify Insmed as “a Best Idea within our coverage universe.”